Incyte set to report Q2 2026 results on Jul. 28, analysts see EPS of $1.61
AI Market Summary
Incyte is set to report Q2 FY2026 results on July 28 pre-market, with consensus expecting EPS of $1.61 (+22.9% YoY). The company has recently beaten earnings estimates, supported by Jakafi sales growth, while Opzelura sales have been a relative soft spot. Reaffirmed full-year revenue guidance reduces uncertainty, but the event remains a classic earnings-driven catalyst that can raise near-term volatility around the release.
Impact level
● Medium
Affected assets
NCSKCRDO2USD/USDT-6.29%
AI Insight · NCSKCRDO2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Incyte (INCY) is scheduled to release its fiscal Q2 2026 earnings before the market opens on Jul. 28, 2026. Analysts expect earnings of $1.61 per share, up 22.9% year over year. The company has beaten Wall Street EPS estimates in three of the past four quarters, including Q1 results showing adjusted EPS of $1.81 on $1.27 billion in revenue, with Jakafi net sales rising 7% to $757.8 million. Opzelura sales of $143 million rose 20% year over year but missed expectations, while Incyte reaffirmed its full-year revenue guidance of $4.77 billion–$4.94 billion.
